Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma
- Thursday, January 20, 2022, 7:12
- PR Newswire
- Add a comment
CAMBRIDGE, Mass., Jan. 20, 2022 /PRNewswire/ — Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced its lead candidate VT1021 will advance into a Phase 2-3 registrational study through the company’s collaboration with the Global…
About the Author
admin has written 21717 stories on this site.